Internal Medicine, Medical Oncology · San Francisco, CA
NPI
1972552784
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
400 Parnassus Ave
San Francisco, CA, 94143
Phone (415) 353-2421
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
478 services
Medicare patients, 2024
85
Average age 73
Drug cost, 2024
$5.4M
626 prescriptions
Company payments, 2025
$20.71
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by James L Rubenstein was code 99215 (office e&m - established), 270 times for 80 patients. In total James L Rubenstein billed 478 services in 11 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 270 | 80 | $124.35 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 135 | 60 | $14.70 | $1,985 |
| 99205 Office E&M - New | Facility | 12 | 12 | $161.33 | $1,936 |
By year: 2022 $31K for 278 services; 2023 $38K for 317 services; 2024 $39K for 478 services.
Medicare prescription drug claims, 2024
In 2024, the drug James L Rubenstein prescribed most often to Medicare patients was Acyclovir, with 92 prescriptions and refills. In total James L Rubenstein wrote 626 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 92 | 198 | 25 | $2,317 |
| Revlimid Lenalidomide | 87 | 87 | 14 | $1.3M |
| Imbruvica Ibrutinib | 79 | 79 | 11 | $2.1M |
| Pomalyst Pomalidomide | 50 | 50 | Under 11 | $1.2M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 47 | 78 | 11 | $125 |
| Levetiracetam Generic | 36 | 57 | Under 11 | $951 |
| Lenalidomide Generic | 36 | 36 | Under 11 | $477K |
| Atovaquone Generic | 23 | 31 | Under 11 | $13K |
| Cresemba Isavuconazonium Sulfate | 21 | 21 | Under 11 | $120K |
| Eliquis Apixaban | 19 | 23 | Under 11 | $12K |
| Entecavir Generic | 19 | 51 | Under 11 | $3,278 |
| Gabapentin Generic | 15 | 20 | Under 11 | $91.57 |
| Brukinsa Zanubrutinib | 12 | 12 | Under 11 | $174K |
Brand drugs: 273 claims; generic drugs: 353 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid James L Rubenstein $20.71 ($20.71 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbvie Inc. with $20.71.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $20.71 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.